September 1, 2015

Principal Investigator(s): 
Michael Debaun, M.D., M.P.H.
Muktar Aliyu, M.D., M.P.H., Dr.P.H.
Najibah Aliyu Galadanci, MBBS, M.P.H.
Lori Chaffin Jordan, M.D., Ph.D.

Primary prevention of stroke in children with Sickle Cell Disease in Sub-Saharan Africa II (R01NS094041)
Strokes in sickle cell anemia (SCA), particularly in children living in Africa, are associated with significant morbidity and an increased rate of premature death. Approximately 80% of the 300,000 children with SCA are born in Africa, of which 10% are expected to have strokes in childhood. Based on our successful feasibility trial in Nigeria for primary stroke prevention in children deemed to be at high risk of stroke because of high transcranial Doppler measurements,6 we are poised to determine if moderate dose hydroxyurea when compared to low dose hydroxyurea, can successfully prevent strokes in high risk children with SCA living in Nigeria and Ghana.